Spark Therapeutics, Inc. (NASDAQ:ONCE) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07.
|
Submission of Matters to a Vote of Security Holders
|
previously announced Annual Meeting of Stockholders (the
Meeting), at which a quorum was present. At the Meeting, the
stockholders of the Company voted on the following four
proposals:
Directors (the Board) as Class II directors for terms expiring at
the 2020 annual meeting of stockholders. The votes cast at the
Meeting were as follows:
|
On the election of Steven M. Altschuler, M.D. as a Class II
director – 22,868,432 shares voted for and 4,990,897 shares withheld. |
|
On the election of Lars G. Ekman, M.D. as a Class II
director – 20,325,883 shares voted for and 7,533,446 shares withheld. |
|
On the election of Katherine A. High, M.D. as a Class II
director – 23,738,362 shares voted for and 4,120,967 shares withheld. |
Companys named executive officers was approved. The votes cast at
the Meeting were as follows: 27,792,316 shares voted for, 60,538
shares voted against and 6,475 shares abstained. There were
1,178,274 broker non-votes for this proposal.
that future advisory votes on the compensation of the Companys
named executive officers be held every year. The votes cast at
the Meeting were as follows: 26,736,686 shares voted one year,
8,652 shares voted two years, 1,112,899 shares voted three years
and 1,092 shares abstained.
the Boards prior recommendation in favor of an annual advisory
shareholder vote on the compensation of the Companys named
executive officers, the Board intends to hold future advisory
votes on the compensation of the Companys named executive
officers every year.
public accounting firm for the Company for the fiscal year ending
December 31, 2017 was ratified. The votes cast at the Meeting
were as follows: 28,972,830 shares voted for, 48,456 shares voted
against and 16,317 shares abstained. There were zero broker
non-votes for this proposal.
About Spark Therapeutics, Inc. (NASDAQ:ONCE)
Spark Therapeutics, Inc. (Spark) is engaged in developing products in the field of gene therapy. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its SPK-RPE65 (voretigene neparvovec) targets genetic blinding conditions known as inherited retinal dystrophies (IRDs). Its product candidates include SPK-CHM and SPK-FIX. Its product development portfolio includes product candidates targeting expression of genes in the liver, with an initial focus on hematologic disorders. It is engaged in the development and commercialization of SPK-FIX product candidates for the treatment of hemophilia B. The Company is developing a lead product candidate for the treatment of a form of Batten disease in SPK-TPP1 program. The Company is also conducting preclinical studies on a product candidate for the treatment of Huntington’s disease, a hereditary genetic disorder. Spark Therapeutics, Inc. (NASDAQ:ONCE) Recent Trading Information
Spark Therapeutics, Inc. (NASDAQ:ONCE) closed its last trading session down -0.17 at 52.01 with 231,513 shares trading hands.
